Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma

IF 4.1 4区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Neuroendocrinology Pub Date : 2025-03-05 DOI:10.1111/jne.70017

Emirhan Harbi, Michael Aschner

{"title":"Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma","authors":"Emirhan Harbi, Michael Aschner","doi":"10.1111/jne.70017","DOIUrl":null,"url":null,"abstract":"Pheochromocytoma and paraganglioma (PPGL) are rare and life-threatening tumors of the adrenal medulla and extra-adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including 64Cu/68Ga-DOTA-SSA, 18F-FDOPA, 18F-FDG, 123I-MIBG, and some emerging molecular imaging agents and PRRT therapies, such as 203Pb VMT-α-NET and 212Pb VMT-α-NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":"37 8","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.70017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Pheochromocytoma and paraganglioma (PPGL) are rare and life-threatening tumors of the adrenal medulla and extra-adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including ⁶⁴Cu/⁶⁸Ga-DOTA-SSA, ¹⁸F-FDOPA, ¹⁸F-FDG, ¹²³I-MIBG, and some emerging molecular imaging agents and PRRT therapies, such as ²⁰³Pb VMT-α-NET and ²¹²Pb VMT-α-NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.

查看原文本刊更多论文

核医学与嗜铬细胞瘤、副神经节瘤诊治展望。

嗜铬细胞瘤和副神经节瘤（PPGL）分别是肾上腺髓质和肾上腺外副神经节的罕见且危及生命的肿瘤。PPGL的治疗取决于准确的诊断和治疗。这篇综述提供了一个非常全面的概述核医学在PPGL的诊断挑战和陷阱，治疗和新阶段研究的一些我们的观点。介绍了64Cu/68Ga-DOTA-SSA、18F-FDOPA、18F-FDG、123I-MIBG等核医学技术，以及203Pb VMT-α-NET和212Pb VMT-α-NET靶向α疗法（TAT）等新兴分子显像剂和PRRT疗法。它还提供了增殖细胞核抗原（PCNA）抑制剂与侵袭性/转移性PPGL治疗药物联合使用的见解。本文通过对最新进展和临床实践的综合综述，旨在指导医护人员提高PPGL的诊断准确性和治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroendocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

6.20%

发文量

137

审稿时长

4-8 weeks

期刊介绍： Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.